Nifty
:
24741.00
Sensex
:
80710.76
6.70 (0.03%)
-7.25 (-0.01%)
Nifty
Sensex
:
:
24741.00
80710.76
6.70 (0.03%)
-7.25 (-0.01%)

Zim Laboratories Ltd.

Pharmaceuticals & Drugs

Rating :
35/99

BSE: 541400 | NSE: ZIMLAB

NSE BSE
73.76
05-Sep-2025
  • Open
  • High
  • Low
  • Previous Close
  •  74.67
  •  75.8
  •  73.35
  •  74.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  60611
  •  4495021.72
  •  128
  •  69.1

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 361.55
  • 38.50
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 471.10
  • N/A
  • 1.45

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 33.26%
  • 7.88%
  • 47.50%
  • FII
  • DII
  • Others
  • 0.03%
  • 0.00%
  • 11.33%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.51
  • 4.29
  • -1.66

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.12
  • 1.92
  • -3.40

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.08
  • 10.68
  • -20.75

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 28.85
  • 29.63

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 1.87
  • 2.24

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 9.73
  • 11.31

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
71.76
81.82
-12.30%
108.73
117.86
-7.75%
96.33
96.29
0.04%
92.14
85.83
7.35%
Expenses
67.50
73.79
-8.52%
94.14
102.22
-7.90%
84.77
84.76
0.01%
82.61
76.50
7.99%
EBITDA
4.26
8.04
-47.01%
14.60
15.65
-6.71%
11.56
11.53
0.26%
9.53
9.32
2.25%
EBIDTM
5.94%
9.82%
13.42%
13.28%
12.00%
11.98%
10.34%
10.86%
Other Income
1.48
1.00
48.00%
1.71
1.53
11.76%
1.76
1.11
58.56%
1.32
1.42
-7.04%
Interest
3.30
2.86
15.38%
2.91
2.28
27.63%
2.73
1.70
60.59%
2.89
1.22
136.89%
Depreciation
4.86
4.94
-1.62%
5.29
3.90
35.64%
4.88
3.94
23.86%
5.00
4.09
22.25%
PBT
-2.43
1.23
-
8.11
11.00
-26.27%
5.70
7.02
-18.80%
2.96
5.44
-45.59%
Tax
-0.56
0.34
-
3.22
2.91
10.65%
1.70
2.23
-23.77%
0.58
1.29
-55.04%
PAT
-1.88
0.90
-
4.88
8.09
-39.68%
4.00
4.79
-16.49%
2.38
4.15
-42.65%
PATM
-2.61%
1.10%
4.49%
6.86%
4.15%
4.97%
2.58%
4.83%
EPS
-0.38
0.18
-
1.00
1.66
-39.76%
0.82
0.98
-16.33%
0.49
0.85
-42.35%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
368.96
379.03
367.42
398.53
333.43
307.26
277.74
335.37
272.80
235.01
268.51
Net Sales Growth
-3.36%
3.16%
-7.81%
19.52%
8.52%
10.63%
-17.18%
22.94%
16.08%
-12.48%
 
Cost Of Goods Sold
161.62
167.85
171.44
198.83
160.35
158.63
143.14
159.51
140.89
119.96
157.72
Gross Profit
207.34
211.18
195.98
199.69
173.08
148.63
134.60
175.86
131.91
115.04
110.79
GP Margin
56.19%
55.72%
53.34%
50.11%
51.91%
48.37%
48.46%
52.44%
48.35%
48.95%
41.26%
Total Expenditure
329.02
335.30
326.09
346.54
292.45
267.50
255.13
293.34
238.02
203.53
239.32
Power & Fuel Cost
-
17.39
13.47
11.09
9.14
7.04
7.47
7.19
5.75
5.35
6.40
% Of Sales
-
4.59%
3.67%
2.78%
2.74%
2.29%
2.69%
2.14%
2.11%
2.28%
2.38%
Employee Cost
-
60.76
53.34
49.32
40.07
35.76
35.35
48.26
40.80
33.00
30.70
% Of Sales
-
16.03%
14.52%
12.38%
12.02%
11.64%
12.73%
14.39%
14.96%
14.04%
11.43%
Manufacturing Exp.
-
38.37
39.34
33.83
29.03
23.40
26.97
13.62
7.82
7.76
7.25
% Of Sales
-
10.12%
10.71%
8.49%
8.71%
7.62%
9.71%
4.06%
2.87%
3.30%
2.70%
General & Admin Exp.
-
20.21
17.98
19.55
15.82
10.72
11.61
14.53
10.85
10.30
8.61
% Of Sales
-
5.33%
4.89%
4.91%
4.74%
3.49%
4.18%
4.33%
3.98%
4.38%
3.21%
Selling & Distn. Exp.
-
24.12
24.48
27.94
32.70
27.96
24.51
45.61
28.22
22.53
22.04
% Of Sales
-
6.36%
6.66%
7.01%
9.81%
9.10%
8.82%
13.60%
10.34%
9.59%
8.21%
Miscellaneous Exp.
-
6.61
6.04
5.98
5.35
3.98
6.07
4.62
3.69
4.62
22.04
% Of Sales
-
1.74%
1.64%
1.50%
1.60%
1.30%
2.19%
1.38%
1.35%
1.97%
2.46%
EBITDA
39.95
43.73
41.33
51.99
40.98
39.76
22.61
42.03
34.78
31.48
29.19
EBITDA Margin
10.83%
11.54%
11.25%
13.05%
12.29%
12.94%
8.14%
12.53%
12.75%
13.40%
10.87%
Other Income
6.27
5.78
5.18
6.41
4.40
2.34
4.52
2.05
3.42
5.51
3.91
Interest
11.83
11.39
6.92
5.58
8.31
10.90
12.65
10.59
9.34
10.47
13.65
Depreciation
20.03
20.11
15.95
17.47
16.03
15.79
14.41
11.42
9.79
9.02
8.76
PBT
14.34
18.01
23.64
35.35
21.04
15.41
0.07
22.07
19.07
17.50
10.69
Tax
4.94
5.84
6.40
10.92
6.49
2.91
-3.23
6.73
5.83
-1.09
0.26
Tax Rate
34.45%
32.43%
27.07%
30.89%
30.85%
28.45%
-4614.29%
30.49%
23.39%
-6.23%
4.85%
PAT
9.38
12.16
17.25
24.43
14.55
7.32
3.30
15.34
19.11
18.59
5.10
PAT before Minority Interest
9.38
12.16
17.25
24.43
14.55
7.32
3.30
15.34
19.11
18.59
5.10
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
2.54%
3.21%
4.69%
6.13%
4.36%
2.38%
1.19%
4.57%
7.01%
7.91%
1.90%
PAT Growth
-47.69%
-29.51%
-29.39%
67.90%
98.77%
121.82%
-78.49%
-19.73%
2.80%
264.51%
 
EPS
1.93
2.50
3.54
5.02
2.99
1.50
0.68
3.15
3.92
3.82
1.05

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
252.24
238.75
200.35
175.71
160.75
153.82
151.12
136.60
118.33
98.96
Share Capital
48.73
48.73
48.73
16.24
16.24
16.18
16.12
8.06
8.03
8.00
Total Reserves
202.16
190.02
151.62
159.47
144.51
137.28
133.77
127.95
109.59
90.34
Non-Current Liabilities
53.42
48.65
30.45
20.01
19.40
22.72
20.19
16.61
18.09
34.75
Secured Loans
40.30
35.60
24.62
18.92
21.83
27.01
19.14
15.91
26.75
33.98
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.41
3.02
4.37
0.77
0.77
Long Term Provisions
0.00
0.00
0.00
0.00
0.01
0.00
0.10
0.00
0.00
0.00
Current Liabilities
166.36
159.43
110.79
147.37
142.04
143.44
156.40
141.40
113.21
123.65
Trade Payables
69.51
62.38
58.24
81.07
64.87
66.00
71.95
66.26
45.05
46.97
Other Current Liabilities
40.80
41.21
29.07
44.71
31.16
26.68
38.65
25.15
18.33
16.71
Short Term Borrowings
52.46
55.04
22.88
17.34
44.60
49.69
40.15
49.56
46.70
56.30
Short Term Provisions
3.60
0.80
0.59
4.24
1.40
1.06
5.65
0.43
3.14
3.68
Total Liabilities
472.02
446.83
341.59
343.09
322.19
319.98
327.71
294.61
249.63
257.36
Net Block
164.28
160.83
108.66
105.64
106.52
115.92
106.01
94.16
88.75
92.19
Gross Block
274.88
266.57
198.66
180.24
165.49
159.23
135.67
112.90
97.77
120.36
Accumulated Depreciation
110.61
105.74
90.01
74.60
58.97
43.31
29.66
18.74
9.02
28.17
Non Current Assets
240.72
219.17
150.63
129.49
130.43
137.94
132.39
121.68
95.86
102.02
Capital Work in Progress
70.46
42.28
26.99
11.74
10.68
9.62
13.32
8.29
3.82
2.93
Non Current Investment
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
Long Term Loans & Adv.
5.16
15.71
14.41
11.78
11.32
10.40
11.72
17.33
2.35
6.36
Other Non Current Assets
0.76
0.31
0.52
0.28
1.85
1.95
1.29
1.84
0.87
0.48
Current Assets
231.31
227.65
190.95
213.59
191.76
182.03
195.32
172.94
153.77
155.34
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
86.47
81.26
53.71
75.28
54.35
56.39
55.05
51.56
35.47
37.72
Sundry Debtors
106.92
100.17
95.25
89.52
72.25
67.93
93.10
89.22
88.18
88.53
Cash & Bank
2.49
10.46
7.52
4.97
8.35
3.95
2.94
3.53
5.61
6.39
Other Current Assets
35.43
2.29
2.56
1.41
56.81
53.76
44.23
28.63
24.52
22.70
Short Term Loans & Adv.
32.33
33.46
31.91
42.41
55.26
52.16
42.83
27.51
23.51
21.49
Net Current Assets
64.94
68.22
80.16
66.23
49.72
38.60
38.92
31.54
40.56
31.69
Total Assets
472.03
446.82
341.58
343.08
322.19
319.97
327.71
294.62
249.63
257.36

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
41.15
16.28
38.17
49.21
31.85
21.92
34.94
36.68
32.07
21.94
PBT
18.01
23.64
35.35
21.04
15.41
0.07
22.07
24.94
17.50
5.36
Adjustment
32.43
22.01
22.16
22.01
25.79
26.25
23.82
12.84
20.78
29.04
Changes in Working Capital
-10.36
-26.79
-12.19
6.58
-8.24
0.56
-9.64
2.96
-3.72
-11.32
Cash after chg. in Working capital
40.08
18.86
45.32
49.64
32.96
26.87
36.25
40.73
34.56
23.08
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
1.08
-2.58
-7.15
-0.43
-1.11
-4.96
-1.31
-4.06
-2.49
-1.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-39.93
-73.01
-36.20
-14.57
-5.88
-19.41
-20.68
-25.83
-7.24
-11.73
Net Fixed Assets
-33.16
-81.96
-32.76
-15.55
-7.23
-19.28
-22.29
-19.60
21.70
Net Investments
-4.81
-0.05
0.00
-0.10
0.00
-3.54
-4.45
0.00
0.00
Others
-1.96
9.00
-3.44
1.08
1.35
3.41
6.06
-6.23
-28.94
Cash from Financing Activity
-9.10
59.53
0.55
-32.97
-25.97
-2.16
-15.16
-9.80
-25.15
-10.35
Net Cash Inflow / Outflow
-7.88
2.80
2.51
1.66
0.00
0.35
-0.90
1.04
-0.32
-0.14
Opening Cash & Equivalents
9.60
6.42
3.42
1.39
1.46
0.50
1.47
0.42
0.74
0.88
Closing Cash & Equivalent
1.95
9.60
6.42
3.42
1.39
1.46
0.50
1.47
0.42
0.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
51.49
49.00
41.12
36.06
32.99
94.84
92.99
84.38
73.25
61.47
ROA
2.65%
4.38%
7.14%
4.37%
2.28%
1.02%
4.93%
7.02%
7.33%
1.95%
ROE
4.97%
7.86%
13.00%
8.65%
4.66%
2.17%
10.73%
15.07%
17.21%
5.29%
ROCE
8.29%
10.11%
16.82%
12.52%
8.70%
5.39%
14.64%
16.46%
14.20%
9.95%
Fixed Asset Turnover
1.40
1.58
2.10
1.93
1.89
1.88
2.70
2.60
2.21
2.43
Receivable days
99.71
97.06
84.61
88.55
83.26
105.81
99.21
118.05
133.84
112.03
Inventory Days
80.76
67.04
59.07
70.95
65.77
73.23
58.02
57.91
55.43
55.29
Payable days
143.40
128.40
127.86
166.10
150.56
175.89
88.19
86.92
85.73
87.08
Cash Conversion Cycle
37.07
35.70
15.82
-6.61
-1.53
3.15
69.04
89.04
103.54
80.25
Total Debt/Equity
0.45
0.44
0.30
0.29
0.50
0.59
0.52
0.60
0.68
0.98
Interest Cover
2.58
4.41
7.34
3.53
1.94
1.01
3.08
3.67
2.67
1.39

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Zim Laboratories' arm gets nod for investment of upto AED 4,50,000 in share capital of ZIM Scientific Office L.L.C
    8th Aug 2025, 15:09 PM

    The Board of Directors of the company in their meeting held on August 07, 2025, has approved the same

    Read More
  • Zim Laboratories - Quarterly Results
    7th Aug 2025, 19:49 PM

    Read More
  • ZIM Laboratories gets Marketing Authorization for Tamsulosin Hydrochloride and Dutasteride Capsules in Australia
    4th Aug 2025, 15:41 PM

    This achievement aligns with ZIM’s strategy to leverage its development and manufacturing expertise to build a robust pipeline of differentiated generics for global markets

    Read More
  • ZIM Laboratories gets marketing authorization for Rizatriptan Benzoate Orally Disintegrating Films
    21st Jul 2025, 14:30 PM

    This milestone reflects ZIM’s continued focus on differentiated, technology-driven generics designed to improve treatment adherence and patient experience

    Read More
  • ZIM Laboratories’ arm completes investment in ZIM Scientific Office
    11th Jul 2025, 15:43 PM

    Post investment, the shareholding of the ZIM FZE remains at 100% of the total share capital of ZIM SO

    Read More
  • Zim Laboratories completes investment in SIA ZIM Laboratories
    19th Jun 2025, 12:39 PM

    Post investment, the shareholding of the company remains at 100% of the total share capital of SIA ZIM Laboratories

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.